Sun Pharmaceuticals Industries (BOM:524715) ROCE % : 19.91% (As of Dec. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Sun Pharmaceuticals Industries ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sun Pharmaceuticals Industries's annualized ROCE % for the quarter that ended in Dec. 2024 was 19.91%.

Sun Pharmaceuticals Industries ROCE % Historical Data

The historical data trend for Sun Pharmaceuticals Industries's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharmaceuticals Industries ROCE % Chart

Sun Pharmaceuticals Industries Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

10.61

5.65

8.85

16.89

17.52

Sun Pharmaceuticals Industries Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															18.85	16.88	20.36	20.70	19.91

Sun Pharmaceuticals Industries ROCE % Calculation

Sun Pharmaceuticals Industries's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	113263.6	/	( ( (807435.9 - 199070)	+	(854628.8 - 169844) )	/ 2 )
	=	113263.6	/	( (608365.9	+	684784.8)	/ 2 )
	=	113263.6	/	646575.35
	=	17.52 %

Sun Pharmaceuticals Industries's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	141116.4	/	( ( (881156.6 - 172552.2)	+	(0 - 0) )	/ 1 )
	=	141116.4	/	( ( 708604.4	+	0 )	/ 1 )
	=	141116.4	/	708604.4
	=	19.91 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Sun Pharmaceuticals Industries (BOM:524715) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sun Pharmaceuticals Industries ROCE % Related Terms

Thank you for viewing the detailed overview of Sun Pharmaceuticals Industries's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharmaceuticals Industries Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharmaceuticals Industries Ltd (BOM:524715) » Definitions » ROCE %

Traded in Other Exchanges

SUNPHARMA:India

Address

Western Express Highway, Sun House, Plot No. 201 B/1, Goregaon (East), Mumbai, MH, IND, 400 063

Website

https://www.sunpharma.com

Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.

Sun Pharmaceuticals Industries Headlines

No Headlines